Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 17 Stomach Neoplasms 8 Colorectal Neoplasms 7 Carcinoma, Non-Small-Cell Lung 7 Rectal Neoplasms 5 Neoplasm Metastasis 4 Triple Negative Breast Neoplasms 3 Pancreatic Neoplasms 3 Nasopharyngeal Carcinoma 3 Esophageal Neoplasms 3 Uterine Cervical Neoplasms 2 Solid Tumor 2 Recurrence 2 Lung Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Endometrial Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Spinocerebellar Degenerations 1 Small Cell Lung Carcinoma 1 Resectable NSCLC 1 Ovarian Neoplasms 1 Neuroblastoma 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Metastatic Gastroesophageal Junction Adenocarcinoma 1 Meningeal Carcinomatosis 1 MSI-H 1 Lymphoma, T-Cell, Peripheral 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large B-Cell, Diffuse 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Resectable NSCLC × sintilimab × 1 year × Clear all

NCT07492342 2026-03-25

K-NADIR

The First Affiliated Hospital of Guangzhou Medical University

Phase 2 Recruiting

Resectable NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡